Nasdaq · CIK 0001472091
PDSB PDS Biotechnology Corp
Insider trading from SEC Form 4. Last filing Jul 25, 2025. Close $1.38 on Oct 9, 2026, +587% from the 52-week low and -4% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
9
with a Form 4 at this company
Price and insider trades, last year
PDSBOct 9, 2026 · close 1.38
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at PDS Biotechnology Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 29Weak | Gregory Gene Freitag director buy | $25k 15,060 shares | +33% | - | |
| 34Weak | Stephen C. Glover director buy | $25k 15,061 shares | +24% | - |
Transactions
The last 16 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Lars Boesgaard Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jul 25, 2025 |
| Feb 28, 2024 | Frank Bedu-Addo President/CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Jul 25, 2025 |
| Feb 28, 2024 | Spencer D. Brown Senior VP, General Counsel | AGrant or award Employee Stock Option (Right to Buy)derivative | +56,000 | $0.00 | $0 | 56,000 | Jul 25, 2025 |
| Feb 28, 2024 | Gregory Conn Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +46,648 | $0.00 | $0 | 46,648 | Jul 25, 2025 |
| Jun 12, 2025 | Frank Bedu-Addo President/CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jul 25, 2025 |
| Jun 12, 2025 | Spencer D. Brown Senior VP, General Counsel | AGrant or award Employee Stock Option (Right to Buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jul 25, 2025 |
| Jun 12, 2025 | Gregory Conn Chief Scientific Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Jul 25, 2025 |
| Jun 11, 2025 | Kamil Ali-Jackson director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| Jun 11, 2025 | Otis W Brawley director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| Jun 11, 2025 | Gregory Gene Freitag director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| Jun 11, 2025 | Stephen C. Glover director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| Jun 11, 2025 | Ilian Iliev director | AGrant or award Employee Stock Option (Right to Buy)derivative | +22,700 | $0.00 | $0 | 22,700 | Jun 11, 2025 |
| Feb 28, 2025 | Gregory Gene Freitag director | POpen-market purchase Common Stock | +15,060 | $1.66 | $25k | 61,213 | Mar 3, 2025 |
| Feb 28, 2025 | Stephen C. Glover director | POpen-market purchase Common Stock | +15,061 | $1.66 | $25k | 78,851 | Mar 3, 2025 |
| Feb 28, 2025 | Gregory Gene Freitag director | POpen-market purchase Common Warrantderivative | +15,060 | - | - | 15,060 | Mar 3, 2025 |
| Feb 28, 2025 | Stephen C. Glover director | POpen-market purchase Common Warrantderivative | +15,061 | - | - | 15,061 | Mar 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Kamil Ali-Jacksondirector
- Frank Bedu-AddoPresident/CEO
- Otis W Brawleydirector
- Lars BoesgaardChief Financial Officer
- Spencer D. BrownSenior VP, General Counsel
- Gregory ConnChief Scientific Officer
- Gregory Gene Freitagdirector
- Stephen C. Gloverdirector, ceo, officer
- Ilian Ilievdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.